2009-2015 年和 2016-2019 年美国先天性巨细胞病毒诊断婴儿中缬更昔洛韦使用的变化。
Changes in Valganciclovir Use Among Infants with Congenital Cytomegalovirus Diagnosis in the United States, 2009-2015 and 2016-2019.
机构信息
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA.
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA.
出版信息
J Pediatr. 2022 Jul;246:274-278.e2. doi: 10.1016/j.jpeds.2022.03.042. Epub 2022 Mar 28.
From 2009-2015 to 2016-2019, the proportion of infants in the US with congenital cytomegalovirus treated with valganciclovir roughly doubled for infants enrolled with employer-sponsored insurance (from 16% to 29%) and Medicaid (from 16% to 36%). The proportion treated with valganciclovir increased for all congenital cytomegalovirus disease severity groups.
从 2009-2015 年到 2016-2019 年，接受缬更昔洛韦治疗的美国先天性巨细胞病毒婴儿的比例，在有雇主赞助保险（从 16%增至 29%）和医疗补助（从 16%增至 36%）的婴儿中大致翻了一番。所有先天性巨细胞病毒疾病严重程度组接受缬更昔洛韦治疗的比例都有所增加。
Zotero 插件